Jun-Ichi Miyatake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun-Ichi Miyatake has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Terufumi Yamaguchi
Department of Hematology
6 shared publications- Yasuhiro Maeda
Department of Hematology, Kinki University School of Medicine, Osaka, Japan
5 shared publications Chikara Hirase
Division of Hematology and Rheumatology, Department of Internal Medicine, Kinki University Faculty of Medicine, Japan
4 shared publications- Itaru Matsumura
Kindai University Faculty of Medicine, Osakasayama, Japan
4 shared publications Akihisa Kanamaru
3 shared publicationsMasaya Kawauchi
Division of Hematology and Rheumatology, Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan
3 shared publications
Latest Publications
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (11) , 1393-1396
HIV-negative Primary Bone Marrow Hodgkin Lymphoma Manifesting with a High Fever Associated with Hemophagocytosis as the Initial Symptom: A Case Report and Review of the Previous Literature
A 68-year-old man was referred to our hospital due to a high fever and pancytopenia. Neither tumors nor infectious lesions were detected. Hemophagocytosis was observed on the bone marrow (BM) smear, although without abnormal cells. Prednisolone therapy was ineffective for the patient's high fever. Later on, we obtained the results of a BM biopsy indicating the presence of infiltration of atypical Reed-Sternberg cells, leading to a diagnosis of HIV-negative primary bone marrow Hodgkin lymphoma (PBMHL). However, the patient died of multiple organ failure before receiving chemotherapy. As the clinical course of PBMHL is rapid, physicians must keep in mind its possibility in similar cases.
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (11) , 1393-1396
HIV-negative Primary Bone Marrow Hodgkin Lymphoma Manifesting with a High Fever Associated with Hemophagocytosis as the Initial Symptom: A Case Report and Review of the Previous Literature
A 68-year-old man was referred to our hospital due to a high fever and pancytopenia. Neither tumors nor infectious lesions were detected. Hemophagocytosis was observed on the bone marrow (BM) smear, although without abnormal cells. Prednisolone therapy was ineffective for the patient's high fever. Later on, we obtained the results of a BM biopsy indicating the presence of infiltration of atypical Reed-Sternberg cells, leading to a diagnosis of HIV-negative primary bone marrow Hodgkin lymphoma (PBMHL). However, the patient died of multiple organ failure before receiving chemotherapy. As the clinical course of PBMHL is rapid, physicians must keep in mind its possibility in similar cases.
- 24 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1947-1952
Clinical importance of human herpes virus-8 and human immunodeficiency virus infection in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that usually develops in immunosuppressed patients infected with human herpes virus-8 (HHV-8) in conjunction with human immunodeficiency virus (HIV) infection. However, there are several reports of HHV-8-related HIV-negative cases and HHV-8-unrelated HIV-negative cases, mainly in immunodeficient and elderly patients. Here, we report one case of HHV-8-related HIV-negative PEL with gastric cancer (case 1) and one case of HHV-8-unrelated HIV-negative effusion-based lymphoma (case 2), both in elderly men. A 73-year-old man and a 79-year-old man were admitted because of lymphomatous effusions, and no mass was detectable in both cases. They were diagnosed as having malignant effusion lymphoma on the basis of cytological findings indicating atypical lymphoid cells and the expression of CD20 and CD79a. To detect evidence of HHV-8 infection in neoplastic cells, immunocytochemical staining for ORF73/ latent nuclear antigen-1 (LNA-1) was performed. The results revealed that case 1 was ORF73-positive, and case 2 was ORF73-negative. Rituximab-based chemotherapy (R-THPCOP: rituximab, pirarubicin, cyclophosphamide, vincristine, prednisolone) was administered to both patients and complete remission was achieved in both. Compared to most HIV-positive PEL cases, these two cases showed a good response to chemotherapy. In cases of PEL, we should focus on HHV-8 infection and HIV status for determining prognosis.
- 24 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1947-1952
Clinical importance of human herpes virus-8 and human immunodeficiency virus infection in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that usually develops in immunosuppressed patients infected with human herpes virus-8 (HHV-8) in conjunction with human immunodeficiency virus (HIV) infection. However, there are several reports of HHV-8-related HIV-negative cases and HHV-8-unrelated HIV-negative cases, mainly in immunodeficient and elderly patients. Here, we report one case of HHV-8-related HIV-negative PEL with gastric cancer (case 1) and one case of HHV-8-unrelated HIV-negative effusion-based lymphoma (case 2), both in elderly men. A 73-year-old man and a 79-year-old man were admitted because of lymphomatous effusions, and no mass was detectable in both cases. They were diagnosed as having malignant effusion lymphoma on the basis of cytological findings indicating atypical lymphoid cells and the expression of CD20 and CD79a. To detect evidence of HHV-8 infection in neoplastic cells, immunocytochemical staining for ORF73/ latent nuclear antigen-1 (LNA-1) was performed. The results revealed that case 1 was ORF73-positive, and case 2 was ORF73-negative. Rituximab-based chemotherapy (R-THPCOP: rituximab, pirarubicin, cyclophosphamide, vincristine, prednisolone) was administered to both patients and complete remission was achieved in both. Compared to most HIV-positive PEL cases, these two cases showed a good response to chemotherapy. In cases of PEL, we should focus on HHV-8 infection and HIV status for determining prognosis.
- 9 November 2012
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 2 (2) , 71-75
A case of intraocular lymphoma with central nervous system involvement and high interleukin-10 levels in both vitreous humor and cerebrospinal fluids: successful treatment with a combination of intravitreal, intrathecal, and systemic therapy
- 9 November 2012
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 2 (2) , 71-75
A case of intraocular lymphoma with central nervous system involvement and high interleukin-10 levels in both vitreous humor and cerebrospinal fluids: successful treatment with a combination of intravitreal, intrathecal, and systemic therapy
- 1 May 2012
- Published by Taylor & Francis in Hematology
- Vol. 17 (3) , 144-150
Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection
The pathogenesis of acquired immunodeficiency syndrome-associated primary central nervous system lymphoma (AIDS-associated PCNSL) remains unclear. However, cell adhesion molecules have been reported to be strongly associated with PCNSL. In this study, we established Epstein–Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) from HIV-positive patients (LCLHIV) and normal individuals (LCLN). The expression of CD18 antigen by LCLHIV was stronger than that by LCLN. We performed a cell adhesion assay using ISO-HAS, which is the human hemangiosarcoma cell line and expresses intercellular adhesion molecule 1 (CD54). The binding rates of LCLHIV and ISO-HAS without stimulation were higher than those of LCLN. Further, we demonstrated that azidothymidine or simvastatin inhibited the binding rates of LCLHIV and ISO-HAS more significantly than those of LCLN. Further, the levels of interleukin (IL)-8, a CD18 inducer, were higher in LCLHIV than in LCLN. We conclude that interaction between IL-8 and CD18 may be critical to AIDS-related PCNSL.
- 1 May 2012
- Published by Taylor & Francis in Hematology
- Vol. 17 (3) , 144-150
Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection
The pathogenesis of acquired immunodeficiency syndrome-associated primary central nervous system lymphoma (AIDS-associated PCNSL) remains unclear. However, cell adhesion molecules have been reported to be strongly associated with PCNSL. In this study, we established Epstein–Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) from HIV-positive patients (LCLHIV) and normal individuals (LCLN). The expression of CD18 antigen by LCLHIV was stronger than that by LCLN. We performed a cell adhesion assay using ISO-HAS, which is the human hemangiosarcoma cell line and expresses intercellular adhesion molecule 1 (CD54). The binding rates of LCLHIV and ISO-HAS without stimulation were higher than those of LCLN. Further, we demonstrated that azidothymidine or simvastatin inhibited the binding rates of LCLHIV and ISO-HAS more significantly than those of LCLN. Further, the levels of interleukin (IL)-8, a CD18 inducer, were higher in LCLHIV than in LCLN. We conclude that interaction between IL-8 and CD18 may be critical to AIDS-related PCNSL.
- Open Access
- 26 October 2011
- Published by IntechOpen
Retrovirus Infection and Retinoid
Retrovirus Infection and Retinoid | InTechOpen, Published on: 2011-10-26. Authors: Yasuhiro Maeda, Masaya Kawauchi, Chikara Hirase, et
- 26 October 2011
- Published by IntechOpen
Open AccessRetrovirus Infection and Retinoid
Retrovirus Infection and Retinoid | InTechOpen, Published on: 2011-10-26. Authors: Yasuhiro Maeda, Masaya Kawauchi, Chikara Hirase, et
- 11 November 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (1) , 150-152
Senescence induction therapy for the treatment of adult T-cell leukemia
- 11 November 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (1) , 150-152
Senescence induction therapy for the treatment of adult T-cell leukemia
- 28 January 2007
- p. 719-23
[Possible therapy with ATRA for adult T-cell leukemia/lymphoma].
- 1 January 2001
- Published by Taylor & Francis in Hematology
- Vol. 5 (6) , 455-462
Exogenous PML/RARα Fusion Gene Responds to All-transRetinoic Acid Results in Differentiation of the Human B Cell Line
The interaction of an exogenous PML/RARα fusion gene, associated with acute promyelocytic leukemia, with all-trans retinoic acid (ATRA) was examined in B-lymphoid cell lines. RPMI8866 cells were transfected with PML/RARα cDNA in the expression vector pGD and two stable transformants (RPMI8866Y-4 and RPMI8866Y-17) were established by selection with G418. ATRA inhibited the growth of those stable transformants, as assessed by [3H]-thymidine incorporation, but had no effect on the growth of control cells stably transformed with neomycin resistant gene alone. ATRA also increased expression of CD38 and immunoglobulin production in RPMI8866Y-4 cells but not in control cells. When these results are taken together, it can be observed that the exogenous PML/RARα fusion gene responds to ATRA, which results in cell differentiation of the human B cell line.
- 1 January 2001
- Published by Taylor & Francis in Hematology
- Vol. 5 (6) , 455-462
Exogenous PML/RARα Fusion Gene Responds to All-transRetinoic Acid Results in Differentiation of the Human B Cell Line
The interaction of an exogenous PML/RARα fusion gene, associated with acute promyelocytic leukemia, with all-trans retinoic acid (ATRA) was examined in B-lymphoid cell lines. RPMI8866 cells were transfected with PML/RARα cDNA in the expression vector pGD and two stable transformants (RPMI8866Y-4 and RPMI8866Y-17) were established by selection with G418. ATRA inhibited the growth of those stable transformants, as assessed by [3H]-thymidine incorporation, but had no effect on the growth of control cells stably transformed with neomycin resistant gene alone. ATRA also increased expression of CD38 and immunoglobulin production in RPMI8866Y-4 cells but not in control cells. When these results are taken together, it can be observed that the exogenous PML/RARα fusion gene responds to ATRA, which results in cell differentiation of the human B cell line.
- 1 January 2000
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 39 (3-4) , 373-383
Establishment of a Myeloid Cell Line, YM711, Characterized by Retinoid Resistance
A myeloid cell line (YM711) was established by transfecting exogenous PML/RARα cDNA into peripheral blood stem cells. The cells were positive for CD33, CD34, CD38, CD13, CD14, and CD11b, Cytochemical examination revealed YM711 cells to be positive for peroxidase, α-naphtyl butyrate esterase, and acid phosphatase as well. Karyotypic analysis showed them to be nearly tetraploid (92 XXYY). Reverse-transcription polymerase chain reaction showed that, although PML/RARα mRNA was detected in YM711, these cells could not be differentiated by all-trans retinoic acid (ATRA). We therefore designated the YM711 cell line as being ATRA resistant. Because YM711 expressed multi drug resistance 1 (MDR-1) mRNA and p-glycoprotein cell surface protein, we assessed whether verapamil and ATRA would induce the differentiation of YM711 cells; they did not. An increased expression of cellular retinoic acid-binding protein (CRABP)-II was also detected on YM711 cells compared with that of HL-60. These results suggest that high level of expression of CRABP-II may contribute to be the mechanism of ATRA resistance. This cell line may be useful in evaluating the mechanism of resistance to retinoid.
- 1 January 2000
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 39 (3-4) , 373-383
Establishment of a Myeloid Cell Line, YM711, Characterized by Retinoid Resistance
A myeloid cell line (YM711) was established by transfecting exogenous PML/RARα cDNA into peripheral blood stem cells. The cells were positive for CD33, CD34, CD38, CD13, CD14, and CD11b, Cytochemical examination revealed YM711 cells to be positive for peroxidase, α-naphtyl butyrate esterase, and acid phosphatase as well. Karyotypic analysis showed them to be nearly tetraploid (92 XXYY). Reverse-transcription polymerase chain reaction showed that, although PML/RARα mRNA was detected in YM711, these cells could not be differentiated by all-trans retinoic acid (ATRA). We therefore designated the YM711 cell line as being ATRA resistant. Because YM711 expressed multi drug resistance 1 (MDR-1) mRNA and p-glycoprotein cell surface protein, we assessed whether verapamil and ATRA would induce the differentiation of YM711 cells; they did not. An increased expression of cellular retinoic acid-binding protein (CRABP)-II was also detected on YM711 cells compared with that of HL-60. These results suggest that high level of expression of CRABP-II may contribute to be the mechanism of ATRA resistance. This cell line may be useful in evaluating the mechanism of resistance to retinoid.
- 1 January 1996
- Published by Japan Society for Clinical Immunology in Japanese Journal of Clinical Immunology
- Vol. 19 (5) , 477-487
Inhibiton of proliferation by retinoic acid on adult T cell leukemia cells.
成人T細胞性白血病(adult T cell leukemia; ATL)患者17例より採取した末梢血単核細胞(peripheral blood mononuclear cells; PBMC)に対してレチノイン酸を添加後72時間までの細胞増殖能, interleukin-2 receptor (IL-2 R/P 55 α, Tac, CD 25)の発現を観察した.その結果,レチノイン酸添加後の[3H]-thymidineの取り込みの減少率により3つのグループ(過反応群,反応群,抵抗群)に分けた.また,レチノイン酸添加前後でCD 25の発現の変化は認められなかった.レチノイン酸反応群において,レチノイン酸添加後9時間よりDNAの断片化が観察され,アポトーシスの誘導が示唆された.しかし,健常人PBMCにレチノイン酸添加培養してもDNAの断片化は観察されなかったことより,レチノイン酸はATL細胞特異的に活性をもつことが示唆された.以上より,レチノイン酸はATLの治療に応用可能であると考えられた.
- 1 January 1996
- Published by Japan Society for Clinical Immunology in Japanese Journal of Clinical Immunology
- Vol. 19 (5) , 477-487
Inhibiton of proliferation by retinoic acid on adult T cell leukemia cells.
成人T細胞性白血病(adult T cell leukemia; ATL)患者17例より採取した末梢血単核細胞(peripheral blood mononuclear cells; PBMC)に対してレチノイン酸を添加後72時間までの細胞増殖能, interleukin-2 receptor (IL-2 R/P 55 α, Tac, CD 25)の発現を観察した.その結果,レチノイン酸添加後の[3H]-thymidineの取り込みの減少率により3つのグループ(過反応群,反応群,抵抗群)に分けた.また,レチノイン酸添加前後でCD 25の発現の変化は認められなかった.レチノイン酸反応群において,レチノイン酸添加後9時間よりDNAの断片化が観察され,アポトーシスの誘導が示唆された.しかし,健常人PBMCにレチノイン酸添加培養してもDNAの断片化は観察されなかったことより,レチノイン酸はATL細胞特異的に活性をもつことが示唆された.以上より,レチノイン酸はATLの治療に応用可能であると考えられた.